LEADER 02493nam0 2200493 i 450 001 VAN00114828 005 20240806100752.638 017 70$2N$a978-3-319-32562-0 100 $a20180213d2016 |0itac50 ba 101 $aeng 102 $aCH 105 $a|||| ||||| 200 1 $aGroup sequential and confirmatory adaptive designs in clinical trials$fGernot Wassmer, Werner Brannath 210 $a[Cham]$cSpringer$d2016 215 $aXVI, 301 p.$cill.$d24 cm 410 1$1001VAN00114829$12001 $aSpringer Series in Pharmaceutical Statistics$1210 $aBerlin [etc.]$cSpringer 500 1$3VAN00242414$aGroup sequential and confirmatory adaptive designs in clinical trials$91523374 606 $a62-XX$xStatistics [MSC 2020]$3VANC022998$2MF 606 $a62H15$xHypothesis testing in multivariate analysis [MSC 2020]$3VANC030964$2MF 606 $a62K05$xOptimal statistical designs [MSC 2020]$3VANC033803$2MF 606 $a62K10$xStatistical block designs [MSC 2020]$3VANC023659$2MF 606 $a62Kxx$xDesign of statistical experiments [MSC 2020]$3VANC023621$2MF 606 $a62N02$xEstimation in survival analysis and censored data [MSC 2020]$3VANC033692$2MF 606 $a62N03$xTesting in survival analysis and censored data [MSC 2020]$3VANC033860$2MF 606 $a62P10$xApplications of statistics to biology and medical sciences; meta analysis [MSC 2020]$3VANC024649$2MF 606 $a92-XX$xBiology and other natural sciences [MSC 2020]$3VANC020839$2MF 606 $a92B15$xGeneral Biostatistics [MSC 2020]$3VANC026442$2MF 610 $aAdaptive designs$9KW:K 610 $aClinical Trials$9KW:K 610 $aGroup sequential designs$9KW:K 610 $aMultiple hypotheses$9KW:K 610 $aSample Size$9KW:K 620 $aCH$dCham$3VANL001889 700 1$aWassmer$bGernot$3VANV088855$0755933 701 1$aBrannath$bWerner$3VANV088856$0755934 712 $aSpringer $3VANV108073$4650 801 $aIT$bSOL$c20240906$gRICA 856 4 $uhttp://dx.doi.org/10.1007/978-3-319-32562-0$zE-book ? Accesso al full-text attraverso riconoscimento IP di Ateneo, proxy e/o Shibboleth 899 $aBIBLIOTECA CENTRO DI SERVIZIO SBA$2VAN15 912 $fN 912 $aVAN00114828 950 $aBIBLIOTECA CENTRO DI SERVIZIO SBA$d15CONS SBA EBOOK 2288 $e15EB 2288 20180213 996 $aGroup sequential and confirmatory adaptive designs in clinical trials$91523374 997 $aUNICAMPANIA